Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07821424) titled 'Wucao Anfu Formula as Adjunctive Treatment for Immune Checkpoint Inhibitor-Related Rash' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Condition:
Immune Checkpoint Inhibitor-related Rash
Immune-related Adverse Events
Intervention:
Other: Wucao Anfu Formula
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: September 5, 2026
Target Sample Size: 72
To kn...